CoChat

Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates

Open access
Passegué, Emmanuelle, Wagers, Amy J., Giuriato, Sylvie, Anderson, Wade C., Weissman, Irving L. · 2005 · The Journal of Experimental Medicine

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Knowledge of the molecular networks controlling the proliferation and fate of hematopoietic stem cells (HSC) is essential to understand their function in maintaining blood cell production during normal hematopoiesis and upon clinical transplantation. Using highly purified stem and progenitor cell populations, we define the proliferation index and status of the cell cycle machinery at discrete stages of hematopoietic differentiation and during cytokine-mediated HSC mobilization. We identify distinct sets of cell cycle proteins that specifically associate with differentiation, self-renewal, and maintenance of quiescence in HSC and progenitor cells. Moreover, we describe a striking inequality of function among in vivo cycling and quiescent HSC by demonstrating that their long-term engraftment potential resides predominantly in the G(0) fraction. These data provide a direct link between HSC proliferation and function and identify discrete molecular targets in regulating HSC cell fate decisions that could have implications for both the therapeutic use of HSC and the understanding of leukemic transformation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20050967

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Cell cycle status in the pool of multipotent bone marrow cells. (A) FACS sorting conditions used to purify LT-HSC, ST-HSCF, and MPPF. (B) Cell cycle analyses of purified populations by H/PY (top, contour plot) and PI (bottom, histogram) staining. The percentages of cells in G0 (H2N/PY−), G1 (H2N/PY+), or S-G2/M (H>2N-4N/PY+) and in sub2N (<2N), G0/G1 (=2N), S (>2N and <4N), and/or G2/M (=4N) are indicated. (C) Scheme of the BrdU incorporation experiment. 1 mg BrdU (n = 20 mice/time point) was injected intraperitoneally at the start of the kinetic (t = 0) and every 6 h thereafter, and BM cells were harvested after 1 h (t = 1 h; one injection of BrdU), 12 h (t = 12 h; two injections of BrdU), and 24 h (t = 24 h; four injections of BrdU). (D) Short-term kinetics of BrdU incorporation. At the indicated time after BrdU injection, each population was purified by double FACS sorting, and analyzed by flow cytometry for BrdU/PI staining (dot plots). The percentage of BrdU+ cells is indicated (*, potential background). Histograms (right) indicate the changes over time in BrdU fluorescence intensity.
Figure 1. Cell cycle status in the pool of multipotent bone marrow cells. (A) FACS sorting conditions used to purify LT-HSC, ST-HSCF, and MPPF. (B) Cell cycle analyses of purified populations by H/PY (top, contour plot) and PI (bottom, histogram) staining. The percentages of cells in G0 (H2N/PY−), G1 (H2N/PY+), or S-G2/M (H>2N-4N/PY+) and in sub2N (<2N), G0/G1 (=2N), S (>2N and <4N), and/or G2/M (=4N) are indicated. (C) Scheme of the BrdU incorporation experiment. 1 mg BrdU (n = 20 mice/time point) was injected intraperitoneally at the start of the kinetic (t = 0) and every 6 h thereafter, and BM cells were harvested after 1 h (t = 1 h; one injection of BrdU), 12 h (t = 12 h; two injections of BrdU), and 24 h (t = 24 h; four injections of BrdU). (D) Short-term kinetics of BrdU incorporation. At the indicated time after BrdU injection, each population was purified by double FACS sorting, and analyzed by flow cytometry for BrdU/PI staining (dot plots). The percentage of BrdU+ cells is indicated (*, potential background). Histograms (right) indicate the changes over time in BrdU fluorescence intensity.CC BY-NC-SA · PubMed Central
Figure 2. Cell cycle status in progenitor and mature cell populations. (A and B) FACS sorting conditions used to purify myeloid progenitors (CMP, GMP, and MEP), mature Gr, lymphoid progenitors (CLP), and mature splenic B cells (B). (C and D) Short-term kinetics of BrdU incorporation (n = 5 mice/time point). At the indicated time after BrdU injection, each population was first purified by double FACS sorting and then analyzed by flow cytometry for BrdU/PI staining (dot plots). The percentages of BrdU+ cells are indicated. Histograms on the left represent intracellular PI staining (with the percentage of cells in G0/G1, S, and/or G2/M indicated), and histograms on the right represent the changes over time in BrdU fluorescence intensity.
Figure 2. Cell cycle status in progenitor and mature cell populations. (A and B) FACS sorting conditions used to purify myeloid progenitors (CMP, GMP, and MEP), mature Gr, lymphoid progenitors (CLP), and mature splenic B cells (B). (C and D) Short-term kinetics of BrdU incorporation (n = 5 mice/time point). At the indicated time after BrdU injection, each population was first purified by double FACS sorting and then analyzed by flow cytometry for BrdU/PI staining (dot plots). The percentages of BrdU+ cells are indicated. Histograms on the left represent intracellular PI staining (with the percentage of cells in G0/G1, S, and/or G2/M indicated), and histograms on the right represent the changes over time in BrdU fluorescence intensity.CC BY-NC-SA · PubMed Central
Figure 3. Proliferation index and status of the cell cycle machinery during hematopoietic differentiation. (A) Semilogarithmic plot giving the proportion of BrdU-negative stem and progenitor cells. (B) Schematic and color coded representation correlating the proliferation index (right) of each stem and progenitor compartment with their frequency in vivo (left). The different lineages of mature cells produced by each progenitor population are also indicated. B, B lymphocytes; T, T lymphocytes; NK: natural killer cells; E: erythrocytes; Mk: megakaryocytes; MΦ: macrophages. (C) Analysis by qRT-PCR of the expression levels of various components and regulators of the cell cycle machinery during hematopoietic differentiation. Each value has been standardized for β-actin expression levels. For each gene, the relative expression levels in stem, progenitor (prog), and mature cell (mature) populations are expressed as fold induction compared with the levels (set to 1) detected in LT-HSC (except for cyclin B1, in which ST-HSCF was used instead). Results (means ± SD) are obtained from three independently sorted sets of populations. *, P ≤ 0.001; Δ, P ≤ 0.01; o, P ≤ 0.05. nd, not detectable.
Figure 3. Proliferation index and status of the cell cycle machinery during hematopoietic differentiation. (A) Semilogarithmic plot giving the proportion of BrdU-negative stem and progenitor cells. (B) Schematic and color coded representation correlating the proliferation index (right) of each stem and progenitor compartment with their frequency in vivo (left). The different lineages of mature cells produced by each progenitor population are also indicated. B, B lymphocytes; T, T lymphocytes; NK: natural killer cells; E: erythrocytes; Mk: megakaryocytes; MΦ: macrophages. (C) Analysis by qRT-PCR of the expression levels of various components and regulators of the cell cycle machinery during hematopoietic differentiation. Each value has been standardized for β-actin expression levels. For each gene, the relative expression levels in stem, progenitor (prog), and mature cell (mature) populations are expressed as fold induction compared with the levels (set to 1) detected in LT-HSC (except for cyclin B1, in which ST-HSCF was used instead). Results (means ± SD) are obtained from three independently sorted sets of populations. *, P ≤ 0.001; Δ, P ≤ 0.01; o, P ≤ 0.05. nd, not detectable.CC BY-NC-SA · PubMed Central
Figure 4. Cell cycle status in mobilized HSC. (A) Schematic of the Cy/G treatment used to mobilize HSC. Mice were injected intraperitoneally with a single dose of Cy (4 mg/mouse) and injected subcutaneously with recombinant human G (5 μg/mouse) for two successive days (D2 Cy/G treatment) or 4 successive days (D4 Cy/G treatment). For the BrdU experiments, mice were injected intraperitoneally with BrdU (n = 15 normal mice, 3 D2 mice, or 7 D4 mice, respectively, per time point) 1 h (t = 1 h) or 12 h (t = 12 h, with repeated injection at 6 h) before killing them at the end of the D2 or D4 Cy/G treatment. Histograms illustrate the increased numbers of KTLS HSC found in BM, spleen (spl), blood (bld), or mpb at D2 and D4 Cy/G treatment compared with untreated mice (reference 4). (B) Intracellular PI staining analysis of DNA content. The percentages of cells in G0/G1, S, and/or G2/M are indicated. (C) Kinetics of BrdU incorporation. At the indicated times after BrdU injection, each population of HSC was first purified by double FACS sorting and then analyzed by flow cytometry for BrdU/PI staining (dot plots). The percentages of BrdU+ cells are indicated. Histograms at the bottom indicate the changes over time in BrdU fluorescence intensity.
Figure 4. Cell cycle status in mobilized HSC. (A) Schematic of the Cy/G treatment used to mobilize HSC. Mice were injected intraperitoneally with a single dose of Cy (4 mg/mouse) and injected subcutaneously with recombinant human G (5 μg/mouse) for two successive days (D2 Cy/G treatment) or 4 successive days (D4 Cy/G treatment). For the BrdU experiments, mice were injected intraperitoneally with BrdU (n = 15 normal mice, 3 D2 mice, or 7 D4 mice, respectively, per time point) 1 h (t = 1 h) or 12 h (t = 12 h, with repeated injection at 6 h) before killing them at the end of the D2 or D4 Cy/G treatment. Histograms illustrate the increased numbers of KTLS HSC found in BM, spleen (spl), blood (bld), or mpb at D2 and D4 Cy/G treatment compared with untreated mice (reference 4). (B) Intracellular PI staining analysis of DNA content. The percentages of cells in G0/G1, S, and/or G2/M are indicated. (C) Kinetics of BrdU incorporation. At the indicated times after BrdU injection, each population of HSC was first purified by double FACS sorting and then analyzed by flow cytometry for BrdU/PI staining (dot plots). The percentages of BrdU+ cells are indicated. Histograms at the bottom indicate the changes over time in BrdU fluorescence intensity.CC BY-NC-SA · PubMed Central
Figure 5. Proliferation index and status of cell cycle machinery during HSC mobilization. (A) Semilogarithmic plot giving the proportion of BrdU-negative HSC in untreated mice and mice that received D2 and D4 Cy/G treatment. (B) Schematic and color-coded representation correlating the proliferation index of each HSC population following D2 and D4 Cy/G treatment with their pool size in vivo. (C) Analysis by qRT-PCR of the expression levels of various components and regulators of the cell cycle machinery following D2 and D4 Cy/G treatment. Results represent means ± SD of duplicate measurement performed on three independently sorted sets of HSC populations. Each value has been standardized for β-actin expression levels and is expressed as fold induction compared with the levels (set to 1) detected in untreated BM HSC. *, P ≤ 0.001; Δ, P ≤ 0.01; o, P ≤ 0.05.
Figure 5. Proliferation index and status of cell cycle machinery during HSC mobilization. (A) Semilogarithmic plot giving the proportion of BrdU-negative HSC in untreated mice and mice that received D2 and D4 Cy/G treatment. (B) Schematic and color-coded representation correlating the proliferation index of each HSC population following D2 and D4 Cy/G treatment with their pool size in vivo. (C) Analysis by qRT-PCR of the expression levels of various components and regulators of the cell cycle machinery following D2 and D4 Cy/G treatment. Results represent means ± SD of duplicate measurement performed on three independently sorted sets of HSC populations. Each value has been standardized for β-actin expression levels and is expressed as fold induction compared with the levels (set to 1) detected in untreated BM HSC. *, P ≤ 0.001; Δ, P ≤ 0.01; o, P ≤ 0.05.CC BY-NC-SA · PubMed Central
Figure 6. Molecular control of quiescence. Analysis by qRT-PCR of the expression levels of various regulators of G0 or G0/G1 phase transition in homeostatic proliferation during LT-HSC differentiation toward ST-HSCF and MPPF and stress-induced HSC self-renewing proliferation following D2 and D4 Cy/G treatment. The results represent the means ± SD of duplicate measurements performed on three independently sorted sets of populations. Each value has been standardized for β-actin expression levels and is expressed as fold induction compared with the levels (set to 1) detected in LT-HSC or untreated BM HSC. *, P ≤ 0.001; Δ, P ≤ 0.01; o, P ≤ 0.05.
Figure 6. Molecular control of quiescence. Analysis by qRT-PCR of the expression levels of various regulators of G0 or G0/G1 phase transition in homeostatic proliferation during LT-HSC differentiation toward ST-HSCF and MPPF and stress-induced HSC self-renewing proliferation following D2 and D4 Cy/G treatment. The results represent the means ± SD of duplicate measurements performed on three independently sorted sets of populations. Each value has been standardized for β-actin expression levels and is expressed as fold induction compared with the levels (set to 1) detected in LT-HSC or untreated BM HSC. *, P ≤ 0.001; Δ, P ≤ 0.01; o, P ≤ 0.05.CC BY-NC-SA · PubMed Central
Figure 7. Molecular networks linking proliferation and cell fate decision in HSC and progenitor cells. Summary of the proliferation index, phase of the cell cycle, and status of the cell cycle machinery associated with differentiation, self-renewal, or long-term engraftment capacity in HSC and progenitor cells. Several regulators of the cell cycle found to be specifically associated with maintenance of quiescence, differentiation, self-renewal, expansion, and mobilization are identified (underlined and bold). Such genes represent potential targets to encourage self-renewal, prevent differentiation, and reestablish quiescence during ex vivo expansion of HSC for clinical transplantation. They also represent potential targets for deregulation during leukemic transformation.
Figure 7. Molecular networks linking proliferation and cell fate decision in HSC and progenitor cells. Summary of the proliferation index, phase of the cell cycle, and status of the cell cycle machinery associated with differentiation, self-renewal, or long-term engraftment capacity in HSC and progenitor cells. Several regulators of the cell cycle found to be specifically associated with maintenance of quiescence, differentiation, self-renewal, expansion, and mobilization are identified (underlined and bold). Such genes represent potential targets to encourage self-renewal, prevent differentiation, and reestablish quiescence during ex vivo expansion of HSC for clinical transplantation. They also represent potential targets for deregulation during leukemic transformation.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 1997, Exp. Hematol., 25, 445

Cited by

See all 759

Metadata

Authors
Passegué, E., Wagers, A. J., Giuriato, S., Anderson, W. C., & Weissman, I. L.
Affiliations
  • 1Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305
  • Stanford Medicine (US)
Venue
The Journal of Experimental Medicine
Published
2005-12-05
Volume
202
Issue
11
Pages
1599-1611
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2105495977
Cited by
646
References
36
Citations by year
2026: 11 · 2025: 11 · 2024: 25 · 2023: 19 · 2022: 29 · 2021: 27 · 2020: 23 · 2019: 27 · 2018: 29 · 2017: 31 · 2016: 39 · 2015: 47 · 2014: 40 · 2013: 39 · 2012: 35
FWCI
18.51
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
Funders
  • Lymphoma Research Foundation
  • Amgen
  • Leukemia and Lymphoma Society
  • National Institutes of Health
  • National Cancer Institute (CA 86017, CA 55209, R01CA086017)
Topics
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hematology › Blood disorders and treatments
Keywords
hematopoietic stem cells, progenitor cells, cell cycle, cell proliferation, HSC quiescence, self-renewal, hematopoietic differentiation, hematopoietic stem cell mobilization, engraftment potential, gene expression, leukemic transformation, hematopoiesis
MeSH terms
Animals, Cell Differentiation, Cell Separation, Cell Transformation, Neoplastic, Gene Expression Regulation, Graft Survival, Hematopoiesis, Hematopoietic Stem Cells, Humans, Leukemia, Resting Phase, Cell Cycle, Hematopoietic Stem Cell Transplantation, Hematopoietic Stem Cell Mobilization, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.